Introduction: The efficacy and safety of canagliflozin, a sodium glucose co-transporter
antihyperglycemic therapies. The primary objective of this prespecified substudy was to assess change from baseline to 18 weeks in HbA1c among patients on sulfonylurea monotherapy. canagliflozin 100 mg and placebo (15%, 0%, and 4.4%, respectively). Adverse events (AEs) of male and female genital mycotic infections, pollakiuria, and thirst were more common with canagliflozin.
Results
Conclusions: Canagliflozin added to ongoing sulfonylurea monotherapy produced improvements in HbA1c, FPG, and body weight, with an increased incidence of AEs consistent with the mechanism of action of SGLT2 inhibition.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive disease that often requires combination therapy with antihyperglycemic agents (AHAs) to achieve and maintain glycemic control [1] .
Metformin is the most widely recommended initial monotherapy approach, but some patients are started first with sulfonylureas either for intolerance to metformin or because of physician and/or patient preferences despite the known adverse effects, such as hypoglycemia and weight gain [1] . As the sulfonylurea glucose-lowering effects are not sustained, many patients fail to achieve individualized glycemic targets and will need additional therapy [2, 3] . Accordingly, the availability of new agents that can lower blood glucose levels with good safety and tolerability, without increasing hypoglycemia risk and ideally neutralizing the sulfonylurea-induced weight gain, may have significant potential in the future management of the condition.
Canagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved in the United States and elsewhere as an adjunct to diet and exercise to improve glycemic control in adults with T2DM [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Treatment produces significant urinary glucose loss with beneficial effects on glycemic control, body weight, and blood pressure (BP) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Small increases in low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) have been observed, with the ratio remaining unchanged [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Canagliflozin is not associated with hypoglycemia when used in isolation, although rates may be increased when used in conjunction with insulin or insulin secretagogues [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The risks of genital mycotic infections and lower urinary tract infections, but not upper urinary tract infections, are elevated with canagliflozin [18, 19] .
This report defines the effects of canagliflozin on indicators of glycemia, safety, and tolerability compared to placebo in a subset of patients who were on background sulfonylurea monotherapy in a prespecified substudy of the CANagliflozin cardioVascular Assessment Study (CANVAS).
METHODS

Overall Design of the CANVAS Trial
CANVAS is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. A total of 4330 individuals have been randomized to placebo, canagliflozin 100 mg or canagliflozin 300 mg (Janssen Pharmaceuticals, Inc.; Titusville, NJ, USA) [20] .
Objectives and Specific Hypotheses for the Sulfonylurea Substudy
The prespecified CANVAS sulfonylurea substudy was designed to determine the effects of canagliflozin when used in addition to sulfonylurea monotherapy on efficacy, safety, and tolerability in patients with T2DM with inadequate glycemic control at 18 weeks without compromising the masked study design of the entire study cohort. The objectives of the substudy were to assess the changes in glycated hemoglobin (HbA1c) and effects on safety and tolerability with canagliflozin 100 and 300 mg compared to placebo at 18 weeks. A greater reduction in HbA1c with each dose of canagliflozin compared to placebo was the primary hypothesis to be tested.
Secondary objectives of the substudy were to assess the effects of canagliflozin 100 and 300 mg compared to placebo on body weight, fasting plasma glucose (FPG), proportion of participants reaching HbA1c \7.0%, systolic and diastolic BP, fasting plasma lipids (i.e., triglycerides, HDL-C, LDL-C, total cholesterol, and LDL-C to HDL-C ratio) at 18 weeks. Prespecified hypotheses were evaluated for effects on body weight, FPG, proportion of participants reaching HbA1c \7.0%, systolic BP, triglycerides, and HDL-C.
Recruitment
Patient recruitment methods for CANVAS (ClinicalTrials.gov Identifier: NCT01032629) have been previously described [20] .
Participant Inclusion and Exclusion
Criteria
Participants in the CANVAS trial are men and women aged C30 years with T2DM with inadequate glycemic control (HbA1c C7.0%
and B10.5%) on current antihyperglycemic therapies and at increased risk of cardiovascular disease [20] . The specific inclusion and exclusion criteria and the overall CANVAS trial design (including screening and run-in procedures, randomization, and follow-up procedures) have been previously published [20] .
The subset included in the sulfonylurea substudy are the participants who were taking 
Compliance with Ethics
The study is being conducted in accordance with the ethical standards of the responsible 
Baseline Characteristics of Participants
Baseline demographic and disease characteristics were generally similar across treatment groups (Table 1) . At entry to the study, mean age was Mean ± SD duration of T2DM, years 11.4 ± 6.7 10.6 ± 5.9 8.4 ± 6.2 10.2 ± 6.4
Mean ± SD HbA1c, % 8. Table 2 ; Fig. 2 ) and a higher proportion of patients treated with canagliflozin 100 and 300 mg achieved HbA1c \7.0% versus placebo (25.0% and 33.3% vs 5.0%, respectively). FPG was also lower with both doses ( Fig. 3 ; Table 2 ). There was also a statistically significant reduction in the secondary outcome of body weight with canagliflozin 300 mg but not canagliflozin 100 mg (Fig. 4; Table 2 ). There were no notable differences detected in systolic BP with canagliflozin 100 or 300 mg (Table 2) . Clear effects on blood lipids were not apparent, with large CIs about most estimates (Fig. 5) . (Table 3 ). Small to moderate mean percent changes from baseline in serum creatinine were observed with canagliflozin 100 and 300 mg and placebo (4.1%, 9.9%, and 5.7%, respectively). The largest increase in serum creatinine occurred by week 6 in both the canagliflozin 100 and 300 mg groups, and the levels were trending toward baseline by week 18. Similar but reciprocal differences in Fig. 2 Effects of canagliflozin on HbA1c (LOCF). CANA canagliflozin, HbA1c glycated hemoglobin, LOCF last observation carried forward, LS least squares, PBO placebo, SE standard error, wk week Fig. 3 Effects of canagliflozin on FPG (LOCF). CANA canagliflozin, FPG fasting plasma glucose, LOCF last observation carried forward, LS least squares, PBO placebo, SE standard error, wk week. Asterisk Not statistically significant vs PBO based on the hypothesis testing sequence (nominal P\0.001) the mean percent change from baseline in eGFR were observed with canagliflozin 100 and 300 mg and placebo (-2.5%, -9.6%, and -4.7%, respectively).
Effects of Canagliflozin on
DISCUSSION
The addition of canagliflozin to background sulfonylurea monotherapy was efficacious, with further placebo-adjusted decreases of HbA1c of -0.74% and -0.83% for canagliflozin 100 and 300 mg, respectively, at 18 weeks. Furthermore, the reductions in HbA1c were accompanied by a significant decrease in body weight for the 300-mg dose (-1.8%) although not for the 100-mg dose. Canagliflozin 100 mg has been associated with consistent weight loss in other were also inconsistent and nonsignificant, but the overall pattern appeared to be similar to (placebo-subtracted differences of 28.3% vs 20.0%, respectively).
We and others have previously reported that the additional efficacy effects of the 300-mg over the 100-mg dose were achieved at the expense of an increased risk of drug-related AEs [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . By contrast, (almost certainly as the result of the much smaller study numbers), osmotic diuresis-related (e.g., polyuria, pollakiuria, thirst) and volume-related AEs (e.g., postural dizziness, orthostatic hypotension, hypotension, syncope, presyncope) were similar in all treatment groups, with no difference between the 2 canagliflozin doses. We should not, however, conclude that the combination of canagliflozin with a sulfonylurea provides a protective effect against these side effects, and identifying patients potentially susceptible to AEs will be an important component of a patient-centered approach to diabetes management. At the same time, it reinforces the impression that serious adverse effects are relatively uncommon with this compound.
The other AEs observed with canagliflozin were those generally recognized for SGLT2 inhibitors [21] . Genital mycotic infections were more common with canagliflozin than placebo. As has been reported, they were generally mild or moderate in intensity, were managed with usual therapies, and treatment was continued [19] . There was no evidence of an increased rate of either upper or lower urinary tract infections, although this is a recognized potential complication with this drug class in larger datasets [21] . The observed decline in eGFR is likely to be hemodynamic in origin and was not associated with an excess of renal AEs. The small size of the decline in eGFR and the other favorable metabolic effects suggest that the net impact of canagliflozin on renal outcomes is unlikely to be harmful.
The primary weakness of this study is the relatively small sample size. This almost certainly reflects a decrease in the use of sulfonylureas as initial therapy in general, and the small proportion of diabetic patients managed on sulfonylurea monotherapy. As such, the confidence intervals about many estimates are wide, and, while the point estimates of effects sometimes appear different to those reported in prior studies, it is difficult to know whether this reflects real differences in efficacy and safety or chance. In this context, these substudy findings are best interpreted in the context of the broader experience with canagliflozin in this and other patient groups. The conduct of the analyses at 18 weeks provides estimates of short-term effects only, with the long-term impact of canagliflozin in this group remaining to be established.
CONCLUSION
Canagliflozin appears to offer significant and clinically meaningful benefits when used in conjunction with sulfonylureas with a similar class-effect AE profile. Overall, findings from this study support the efficacy and safety of canagliflozin as add-on to sulfonylurea monotherapy in patients with T2DM and cardiovascular risk. 
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